Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 322

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

Blood (2023) 142 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2023-182289

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy

Grace A Ward, Sean Christiansen, Gabriela Wright, Sheng Wei, Alan F. List, Kenneth Wright, Erika A Eksioglu

Blood (2022) 140 (Supplement 1): 12306–12307.

https://doi.org/10.1182/blood-2022-170340

Published: 2022

Journal Articles

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 4588–4589.

https://doi.org/10.1182/blood-2022-165311

Published: 2022

Journal Articles

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Blood (2022) 140 (16): 1774–1789.

https://doi.org/10.1182/blood.2021014875

Published: 2022

Includes: Supplemental data

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Bijal D. Shah, Caron Jacobson, Scott R. Solomon, Nitin Jain, Mark C. Johnson, Monika Vainorius, Lou Yu, Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien

Blood (2021) 138 (Supplement 1): 302.

https://doi.org/10.1182/blood-2021-150609

Published: 2021

Journal Articles

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Jennifer O'Sullivan, Aaron T. Gerds, Claire N. Harrison, Stephen T. Oh, Angela Hamblin, Sarah A Buckley, Alan F. List, Adam J. Mead

Blood (2021) 138 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2021-149666

Published: 2021

Journal Articles

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

Nitin Jain, Hagop Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark C. Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal D. Shah

Blood (2021) 138 (Supplement 1): 650.

https://doi.org/10.1182/blood-2021-153166

Published: 2021

Journal Articles

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Blood (2020) 136 (24): 2812–2823.

https://doi.org/10.1182/blood.2020006158

Published: 2020

Includes: Supplemental data

Journal Articles

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Blood (2020) 136 (7): 909–913.

https://doi.org/10.1182/blood.2019004352

Published: 2020

Includes: Supplemental data

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes

Grace A Ward, BS, Kathy McGraw, PhD, Amy F McLemore, M.S., Nghi B Lam, M.S., Hsin-An Hou, Benjamin S. Meyer, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 774.

https://doi.org/10.1182/blood-2019-122358

Published: 2019

Journal Articles

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Lisa Pleyer, Michael Leisch, MD, Alexandra Kourakli, MD PhD, Eric Padron, MD, Jaroslaw P. Maciejewski, MD PhD, Blanca Xicoy, MD MSc, Jennifer Kaivers, MD, Johanna Ungerstedt, MD PhD, Sonja Heibl, MD, Peristera Patiou, MD, Anthony M. Hunter, MD, Elvira Mora, MD, Klaus Geissler, MD, Maria Dimou, MD PhD, María-José Jimenez, MD, David Kiesl, MD, Nora-Athina Viniou, MD PhD, Bhumika J. Patel, MD, Montserrat Arnan Sangerman, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD PhD, Athanasios Galanopoulos, MD PhD, Marisa Calabuig, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, MD PhD, Jaroslav Cermak, MD PhD, Andres Jerez, Julia Montoro, MD, Albert Cortés, Alejandro Avendaño Pita, MD, Bernardo López Andrade, MD, Eva Hellstrom Lindberg, MD PhD, Ulrich Germing, MD, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Argiris Symeonidis, MD PhD, Guillermo F. Sanz, MD PhD, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 844.

https://doi.org/10.1182/blood-2019-123941

Published: 2019

Journal Articles

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2019) 134 (Supplement_1): 841.

https://doi.org/10.1182/blood-2019-123064

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 676.

https://doi.org/10.1182/blood-2019-131055

Published: 2019

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

TLR9-Selective Therapeutic Targeting of MDS Clones with a CpG Payload-Delivery Strategy

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

Evidence of NF-ΚB Pathway Activation in Patients with Advanced, High Molecular Risk Myelofibrosis

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes

Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only